Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

por Anliker-Ort, Marion, Dingemanse, Jasper, van den Anker, John, Kaufmann, Priska
Publicado 2020

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in health...

por Berger, Benjamin, Kaufmann, Priska, Berse, Matthias, Treiber, Alexander, Grignaschi, Nathalie, Dingemanse, Jasper
Publicado 2023

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

por Kaufmann, Priska, Okubo, Kaori, Bruderer, Shirin, Mant, Tim, Yamada, Tetsuhiro, Dingemanse, Jasper, Mukai, Hideya
Publicado 2015

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist

por Hoch, Matthias, Darpo, Borje, Remenova, Tatiana, Stoltz, Randall, Zhou, Meijian, Kaufmann, Priska, Bruderer, Shirin, Dingemanse, Jasper
Publicado 2014

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo

por Anliker‐Ort, Marion, Dingemanse, Jasper, Delahaye, Stephane, Janů, Luboš, van den Anker, John, Berger, Benjamin, Kaufmann, Priska
Publicado 2023

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a(1) receptor) antagonist

por Anliker‐Ort, Marion, Hsin, Chih‐hsuan, Krause, Andreas, Pfister, Marc, van den Anker, John, Dingemanse, Jasper, Kaufmann, Priska
Publicado 2023